Raw materials are foundational elements in manufacturing safe, high-quality, and efficacious biological products (1–3). The inherent complexity and sensitivity of biologics necessitate robust risk-management strategies across their development and manufacture (4). Raw-material risk assessments provide a structured framework to identify and control risks — such as variability, contamination, and instability (Figure 1) — that can influence the final product (1, 5).
Is this you? As a journalist, you can create a free Muck Rack account to customize your profile, list your contact preferences, and upload a portfolio of your best work.
Claim your profile